Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAle… Read more
Nymox Pharmaceutical Corporation (NYMXF) - Total Liabilities
Latest total liabilities as of December 2023: $3.80 Million USD
Based on the latest financial reports, Nymox Pharmaceutical Corporation (NYMXF) has total liabilities worth $3.80 Million USD as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nymox Pharmaceutical Corporation - Total Liabilities Trend (2019–2023)
This chart illustrates how Nymox Pharmaceutical Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nymox Pharmaceutical Corporation Competitors by Total Liabilities
The table below lists competitors of Nymox Pharmaceutical Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Montebalito S.A.
MC:MTB
|
Spain | €25.35 Million |
|
Sietel Ltd
AU:SSL
|
Australia | AU$9.16 Million |
|
Enthusiast Gaming Holdings Inc.
PINK:EGLXF
|
USA | $45.62 Million |
|
Yoshiharu Global Co.
NASDAQ:YOSH
|
USA | $14.38 Million |
|
Scandium Interna
TO:SCY
|
Canada | CA$254.21K |
|
KCI SA
WAR:KCI
|
Poland | zł34.50 Million |
|
TGS Esports Inc
V:TGS
|
Canada | CA$3.69 Million |
Liability Composition Analysis (2019–2023)
This chart breaks down Nymox Pharmaceutical Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nymox Pharmaceutical Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nymox Pharmaceutical Corporation (2019–2023)
The table below shows the annual total liabilities of Nymox Pharmaceutical Corporation from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $3.80 Million | +80.35% |
| 2022-12-31 | $2.11 Million | +8.11% |
| 2021-12-31 | $1.95 Million | -11.33% |
| 2020-12-31 | $2.20 Million | +7.69% |
| 2019-12-31 | $2.04 Million | -- |